Drug intelligence / Profile preview

Spikevax KP.2

Development stage: Approved
Lead developer: Moderna
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Spikevax KP.2 is a monovalent, Omicron KP.2–adapted COVID-19 mRNA vaccine developed by Moderna as an updated formulation of Spikevax to provide active immunization against SARS-CoV-2, with antigenic sequence matched to the circulating Omicron KP.2 lineage. It consists of nucleoside-modified messenger RNA encoding the SARS-CoV-2 spike glycoprotein of the KP.2 subvariant, formulated in lipid nanoparticles to enable cellular uptake and transient expression of spike antigen. The expressed spike protein elicits both neutralizing antibodies and cellular immune responses, boosting protection against symptomatic COVID-19, hospitalization, and severe disease in previously vaccinated or infected individuals during the 2024–2025 respiratory virus season.[5][13][14]

Brand names: Spikevax KP.2
Other names: Spikevax Omicron KP.2 COVID-19 vaccine

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on Spikevax KP.2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spikevax KP.2.

Explore the full profile